📊 BIVIW Key Takeaways
Is Biovie Inc.. (BIVIW) a Good Investment?
BioVie is a pre-revenue pharmaceutical company with significant operational losses (-$11.5M operating income) and negative free cash flow (-$7.5M), indicating it is in active development phase with no commercial revenue generation. While the company maintains adequate liquidity with $20.5M cash against only $3.2M liabilities, current burn rate suggests runway of approximately 2.7 years at existing consumption levels. The absence of revenue combined with mounting losses and persistent negative returns on assets (-27.0%) and equity (-31.5%) indicates the company is capital-intensive with unproven commercial viability.
BIOVIE INC. shows weak core fundamentals as a pre-revenue biotech with recurring operating losses, negative operating cash flow, and no demonstrated commercial revenue base. The balance sheet is currently strong because cash materially exceeds liabilities and debt is minimal, but the business remains dependent on external funding unless it can materially improve clinical and commercialization progress. Fundamentally, this is a cash-runway story rather than a profitable operating company today.
Why Buy Biovie Inc.. Stock? BIVIW Key Strengths
- Strong liquidity position with $20.5M cash and 7.25x current ratio providing near-term operational runway
- Minimal debt burden with only $62.5K long-term debt and 0.00x debt-to-equity ratio reducing financial distress risk
- Increased insider activity with 8 Form 4 filings in last 90 days suggesting management confidence or option exercises
- Strong liquidity with $20.54M of cash and current and quick ratios of 7.25x
- Very low leverage, with only $62.50K of long-term debt and near-zero debt/equity
- Equity base remains positive at $19.27M, providing some balance sheet flexibility
BIVIW Stock Risks: Biovie Inc.. Investment Risks
- Zero revenue with no commercial products generating sales, typical pre-clinical or early-stage biotech phase risk
- Negative operating cash flow of -$7.5M annually with current cash providing limited runway before requiring capital raise or achieving major milestones
- Persistent unprofitability with $11.5M operating losses and -31.5% ROE indicating inability to generate returns from equity capital invested
- Negative interest coverage of -1451.3x reflects operating losses exceeding any interest obligations and operational distress
- No revenue generation, making profitability and growth quality unproven
- Ongoing losses are significant, with operating income of -$11.55M and operating cash flow of -$7.46M
- Likely future reliance on external capital if cash burn continues without commercial progress
Key Metrics to Watch
- Revenue generation from any approved product candidates or milestone achievement
- Monthly cash burn rate trend to assess sustainability of current runway
- Clinical trial progression and regulatory approvals for lead drug candidates
- Operating expense management and gross margin upon revenue initiation
- Capital raise requirements and dilution impact on existing shareholders
- Quarterly operating cash burn relative to cash balance
- Any transition from zero revenue to sustainable collaboration, licensing, or product revenue
Biovie Inc.. (BIVIW) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 7.25x current ratio provides a solid financial cushion.
BIVIW Profit Margin, ROE & Profitability Analysis
BIVIW vs Healthcare Sector: How Biovie Inc.. Compares
How Biovie Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Biovie Inc.. Stock Overvalued? BIVIW Valuation Analysis 2026
Based on fundamental analysis, Biovie Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Biovie Inc.. Balance Sheet: BIVIW Debt, Cash & Liquidity
BIVIW Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Biovie Inc..'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-73.05 indicates the company is currently unprofitable.
BIVIW Revenue Growth, EPS Growth & YoY Performance
BIVIW Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2016 | N/A | -$54.6K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Biovie Inc.. Dividends, Buybacks & Capital Allocation
BIVIW SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Biovie Inc.. (CIK: 0001580149)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BIVIW
What is the AI rating for BIVIW?
Biovie Inc.. (BIVIW) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BIVIW's key strengths?
Claude: Strong liquidity position with $20.5M cash and 7.25x current ratio providing near-term operational runway. Minimal debt burden with only $62.5K long-term debt and 0.00x debt-to-equity ratio reducing financial distress risk. ChatGPT: Strong liquidity with $20.54M of cash and current and quick ratios of 7.25x. Very low leverage, with only $62.50K of long-term debt and near-zero debt/equity.
What are the risks of investing in BIVIW?
Claude: Zero revenue with no commercial products generating sales, typical pre-clinical or early-stage biotech phase risk. Negative operating cash flow of -$7.5M annually with current cash providing limited runway before requiring capital raise or achieving major milestones. ChatGPT: No revenue generation, making profitability and growth quality unproven. Ongoing losses are significant, with operating income of -$11.55M and operating cash flow of -$7.46M.
What is BIVIW's revenue and growth?
Biovie Inc.. reported revenue of $0.0.
Does BIVIW pay dividends?
Biovie Inc.. does not currently pay dividends.
Where can I find BIVIW SEC filings?
Official SEC filings for Biovie Inc.. (CIK: 0001580149) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BIVIW's EPS?
Biovie Inc.. has a diluted EPS of $-1.70.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BIVIW a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Biovie Inc.. has a SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BIVIW stock overvalued or undervalued?
Valuation metrics for BIVIW: ROE of -31.5% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy BIVIW stock in 2026?
Our dual AI analysis gives Biovie Inc.. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BIVIW's free cash flow?
Biovie Inc..'s operating cash flow is $-7.5M, with capital expenditures of N/A.
How does BIVIW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -31.5% (avg: 15%), current ratio 7.25 (avg: 2).